Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 maart 2020 bijgewerkt door: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Studie Overzicht

Toestand

Onbekend

Gedetailleerde beschrijving

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Studietype

Ingrijpend

Inschrijving (Verwacht)

50

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Clermont-Ferrand, Frankrijk, 63000
        • CHU de Clermont-Ferrand

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

12 jaar tot 16 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Geen tussenkomst: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
cardiac ectopic fat deposits
Tijdsspanne: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Tijdsspanne: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Tijdsspanne: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Tijdsspanne: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Tijdsspanne: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Tijdsspanne: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Tijdsspanne: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Tijdsspanne: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Tijdsspanne: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Tijdsspanne: Day 0
left myocardial regional function (MRI)
Day 0

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
macrovascularisation
Tijdsspanne: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Tijdsspanne: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Tijdsspanne: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Tijdsspanne: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Tijdsspanne: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Tijdsspanne: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Tijdsspanne: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Tijdsspanne: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Tijdsspanne: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Tijdsspanne: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Tijdsspanne: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Tijdsspanne: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Tijdsspanne: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Tijdsspanne: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Tijdsspanne: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Tijdsspanne: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Tijdsspanne: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Tijdsspanne: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Tijdsspanne: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Tijdsspanne: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Tijdsspanne: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Tijdsspanne: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Tijdsspanne: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Tijdsspanne: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Tijdsspanne: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Tijdsspanne: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Tijdsspanne: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Tijdsspanne: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Tijdsspanne: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Tijdsspanne: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Tijdsspanne: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Tijdsspanne: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Tijdsspanne: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Tijdsspanne: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Tijdsspanne: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Tijdsspanne: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Tijdsspanne: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Tijdsspanne: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Tijdsspanne: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Tijdsspanne: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Tijdsspanne: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Tijdsspanne: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Tijdsspanne: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Tijdsspanne: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Tijdsspanne: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Tijdsspanne: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Tijdsspanne: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Tijdsspanne: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Tijdsspanne: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Tijdsspanne: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Tijdsspanne: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Tijdsspanne: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Tijdsspanne: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Tijdsspanne: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Tijdsspanne: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Tijdsspanne: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Tijdsspanne: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Tijdsspanne: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Tijdsspanne: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Tijdsspanne: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Tijdsspanne: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Tijdsspanne: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Tijdsspanne: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Tijdsspanne: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Tijdsspanne: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Tijdsspanne: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Tijdsspanne: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Tijdsspanne: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Tijdsspanne: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Tijdsspanne: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Tijdsspanne: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Tijdsspanne: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Tijdsspanne: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Tijdsspanne: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Tijdsspanne: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Tijdsspanne: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Tijdsspanne: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Tijdsspanne: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Tijdsspanne: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Tijdsspanne: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Tijdsspanne: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Tijdsspanne: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Tijdsspanne: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Tijdsspanne: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Tijdsspanne: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Tijdsspanne: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Tijdsspanne: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Tijdsspanne: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Tijdsspanne: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Tijdsspanne: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Tijdsspanne: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Tijdsspanne: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Tijdsspanne: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Tijdsspanne: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Tijdsspanne: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Tijdsspanne: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Tijdsspanne: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Tijdsspanne: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Tijdsspanne: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Tijdsspanne: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Tijdsspanne: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Tijdsspanne: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Tijdsspanne: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Tijdsspanne: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Tijdsspanne: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Tijdsspanne: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Tijdsspanne: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Tijdsspanne: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Tijdsspanne: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Tijdsspanne: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Tijdsspanne: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Tijdsspanne: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Tijdsspanne: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Tijdsspanne: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Tijdsspanne: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Tijdsspanne: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Tijdsspanne: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Tijdsspanne: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Tijdsspanne: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Tijdsspanne: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Tijdsspanne: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Tijdsspanne: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Tijdsspanne: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Tijdsspanne: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Tijdsspanne: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Tijdsspanne: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Tijdsspanne: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Tijdsspanne: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Tijdsspanne: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Tijdsspanne: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Tijdsspanne: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Tijdsspanne: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Tijdsspanne: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Tijdsspanne: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Tijdsspanne: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Tijdsspanne: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Tijdsspanne: Day 0
measure of weight in kilograms
Day 0
weight
Tijdsspanne: Month 3
measure of weight in kilograms
Month 3
waist circumference
Tijdsspanne: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Tijdsspanne: Month 3
measure of waist circumference in centimetres
Month 3

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Verwacht)

1 september 2020

Primaire voltooiing (Verwacht)

1 juni 2021

Studie voltooiing (Verwacht)

1 juni 2021

Studieregistratiedata

Eerst ingediend

10 februari 2020

Eerst ingediend dat voldeed aan de QC-criteria

13 maart 2020

Eerst geplaatst (Werkelijk)

17 maart 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 maart 2020

Laatste update ingediend die voldeed aan QC-criteria

13 maart 2020

Laatst geverifieerd

1 februari 2020

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Andere identificatie: ANSM)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Onbeslist

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

3
Abonneren